Eli Lilly Other immunology — Revenue increased by 6.1% to $489.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 532.6%, from $77.30M to $489.00M. Over 4 years (FY 2021 to FY 2025), Other immunology — Revenue shows an upward trend with a 167.5% CAGR.
lly_segment_other_immunology_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.90M | $4.90M | $3.20M | $4.50M | $4.00M | $3.60M | $20.00M | $22.00M | $5.70M | $11.40M | $76.10M | $12.50M | $30.00M | $55.30M | $77.30M | $326.10M | $408.00M | $460.90M | $489.00M |
| QoQ Change | — | -38.0% | -34.7% | +40.6% | -11.1% | -10.0% | +455.6% | +10.0% | -74.1% | +100.0% | +567.5% | -83.6% | +140.0% | +84.3% | +39.8% | +321.9% | +25.1% | +13.0% | +6.1% |
| YoY Change | — | — | — | — | -49.4% | -26.5% | +525.0% | +388.9% | +42.5% | +216.7% | +280.5% | -43.2% | +426.3% | +385.1% | +1.6% | >999% | >999% | +733.5% | +532.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.